Estrogen withdrawal, increased breast cancer risk and the KRAS-variant

The KRAS-variant is a biologically functional, microRNA binding site variant, which predicts increased cancer risk especially for women. Because external exposures, such as chemotherapy, differentially impact the effect of this mutation, we evaluated the association of estrogen exposures, breast cancer (BC) risk and tumor biology in women with the KRAS-variant. Women with BC (n = 1712), the subset with the KRAS-variant (n = 286) and KRAS-variant unaffected controls (n = 80) were evaluated, and hormonal exposures, KRAS-variant status, and pathology were compared. The impact of estrogen withdrawal on transformation of isogenic normal breast cell lines with or without the KRAS-variant was studied. Finally, the association and presentation characteristics of the KRAS-variant and multiple primary breast cancer (MPBC) were evaluated. KRAS-variant BC patients were more likely to have ovarian removal pre-BC diagnosis than non-variant BC patients (p = 0.033). In addition, KRAS-variant BC patients also appeared to have a lower estrogen state than KRAS-variant unaffected controls, with a lower BMI (P < 0.001). Finally, hormone replacement therapy (HRT) discontinuation in KRAS-variant patients was associated with a diagnosis of triple negative BC (P < 0.001). Biologically confirming our clinical findings, acute estrogen withdrawal led to oncogenic transformation in KRAS-variant positive isogenic cell lines. Finally, KRAS-variant BC patients had greater than an 11-fold increased risk of presenting with MPBC compared to non-variant patients (45.39% vs 6.78%, OR 11.44 [3.42–37.87], P < 0.001). Thus, estrogen withdrawal and a low estrogen state appear to increase BC risk and to predict aggressive tumor biology in women with the KRAS-variant, who are also significantly more likely to present with multiple primary breast cancer.

[1]  S. Bhatia.  Genetic variation as a modifier of association between therapeutic exposure and subsequent malignant neoplasms in cancer survivors , 2015, Cancer.

[2]  C. Vecchia,et al.  Second primary cancers in the Vaud and Neuchâtel Cancer Registries , 2015, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[3]  J. Weidhaas,et al.  A let-7 microRNA-Binding Site Polymorphism in KRAS Predicts Improved Outcome in Patients with Metastatic Colorectal Cancer Treated with Salvage Cetuximab/Panitumumab Monotherapy , 2014, Clinical Cancer Research.

[4]  J. Weidhaas,et al.  A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  F. Gemignani,et al.  MicroRNA binding site polymorphisms as biomarkers in cancer management and research , 2014, Pharmacogenomics and personalized medicine.

[6]  Edward S. Kim,et al.  The KRAS-variant and treatment response in BATTLE-1. , 2014 .

[7]  J. Weidhaas,et al.  The KRAS-Variant and miRNA Expression in RTOG Endometrial Cancer Clinical Trials 9708 and 9905 , 2014, PloS one.

[8]  S. Narod.  Bilateral breast cancers , 2014, Nature Reviews Clinical Oncology.

[9]  R. Schwab,et al.  Reproductive risk factors and breast cancer subtypes: a review of the literature , 2014, Breast Cancer Research and Treatment.

[10]  E. Bezak,et al.  Risk of second primary cancer after breast cancer treatment. , 2014, European journal of cancer care.

[11]  J. Weidhaas,et al.  A 3 0-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and / or metastatic head and neck squamous cell carcinoma , 2014 .

[12]  W. Yue,et al.  Aromatase overexpression induces malignant changes in estrogen receptor α negative MCF-10A cells , 2013, Oncogene.

[13]  Lihong Qi,et al.  Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study. , 2013, Journal of the National Cancer Institute.

[14]  Jennifer D. Brooks,et al.  Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Xifeng Wu,et al.  The KRAS-Variant Is Associated with Risk of Developing Double Primary Breast and Ovarian Cancer , 2012, PloS one.

[16]  J. Weidhaas,et al.  A polymorphism in a let-7 microRNA binding site of KRAS in women with endometriosis , 2012, EMBO molecular medicine.

[17]  F. Slack,et al.  A KRAS-variant is a Biomarker of Poor Outcome, Platinum Chemotherapy Resistance and a Potential Target for Therapy in Ovarian Cancer , 2011, Oncogene.

[18]  S. Novaković,et al.  KRAS rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study , 2012, BMC Cancer.

[19]  J. Weidhaas,et al.  miRNAs in the spotlight: Making 'silent' mutations speak up , 2011, Nature Medicine.

[20]  David Tuck,et al.  A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis. , 2011, The Lancet. Oncology.

[21]  L. Shulman,et al.  A KRAS-Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer Risk , 2011 .

[22]  Jennifer D. Brooks,et al.  Body mass index and risk of second primary breast cancer: The WECARE Study , 2011, Breast Cancer Research and Treatment.

[23]  Hoda Anton-Culver,et al.  Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Fernö,et al.  Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial. , 2009, European journal of cancer.

[25]  E. John,et al.  Second primary breast cancer occurrence according to hormone receptor status. , 2009, Journal of the National Cancer Institute.

[26]  M. Thun,et al.  Postmenopausal hormone use and breast cancer associations differ by hormone regimen and histologic subtype , 2009, Cancer.

[27]  F. Slack,et al.  A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. , 2008, Cancer research.

[28]  C. Hogue,et al.  Multiple primary tumours in women following breast cancer, 1973–2000 , 2006, British Journal of Cancer.

[29]  J. Sweasy,et al.  Expression of DNA polymerase {beta} cancer-associated variants in mouse cells results in cellular transformation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Jeffrey C. Miller,et al.  Highly efficient endogenous human gene correction using designed zinc-finger nucleases , 2005, Nature.

[31]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[32]  C. Clarke.  Rasagiline for motor complications in Parkinson's disease , 2005, The Lancet.

[33]  B. Kohler,et al.  Women with multiple primary breast cancers diagnosed within a five year period, 1994–1998 , 2005, Breast Cancer Research and Treatment.

[34]  Young C. Lin,et al.  Transformation of MCF‐10A Human Breast Epithelial Cells by Zeranol and Estradiol‐17β , 2004, The breast journal.

[35]  John Robbins,et al.  National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section , 2004, BMJ : British Medical Journal.

[36]  J. Klijn,et al.  Excess Risk for Contralateral Breast Cancer in CHEK2*1100delC Germline Mutation Carriers , 2004, Breast Cancer Research and Treatment.

[37]  Mark Garton,et al.  Breast cancer and hormone-replacement therapy: the Million Women Study , 2003, The Lancet.

[38]  Jayanta Debnath,et al.  Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. , 2003, Methods.

[39]  W. Thompson,et al.  Epidemiology of contralateral breast cancer. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[40]  S. Dobie,et al.  Prophylactic mastectomy for prevention of breast cancer. , 1999, The Journal of family practice.

[41]  J. Russo,et al.  Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. , 1990, Cancer research.

[42]  Gwyn McClelland.  Survivors , 1891, The Hospital.